Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Hankerchiefon Sep 08, 2020 7:56am

255 Views

Post# 31519113

RE:Feeling good that we have another avenue of Possibilities !

From a different article.....I really like the h

Dr. Kevin Coombs, a leading microbiologist at U of M who’s spearheading the research, says he’s never seen anything like it.

"This technology is showing absolutely amazing high efficacy kill rates, both with and without stimulation," he said.

Theralase’s proprietary technology — dubbed "photo dynamic compounds" or PDCs — are completely non-toxic and safe for normal cells. They produce a destructive form of oxygen that is able to destroy pathogens from the inside out, while leaving healthy cells unscathed.

"Part of what makes the whole thing so special is that it’s unique in being not exactly a vaccine, but more of a therapy," Coombs explained.

ighlighted part:

Thor6570 wrote:
Based on those initial results, Coombs stated, “Theralases’s PDCs show great promise as a potential therapeutic. Given the similar physicochemical properties of all enveloped viruses, including the new coronavirus SARS-CoV-2, I believe Theralase’s PDCs represent an important new anti-viral technology platform and I am very interested in further exploring how these PDCs could be used against COVID-19.”

Theralase CSO Dr. Arkady Mandel noted that the company is moving forward on an “advanced vaccine and therapy based on standardized anti-viral approaches by optimizing its PDCs and anti-cancer technology platforms to prevent and fight enveloped viruses, including coronaviruses, such as COVID-19. We are pleased to announce very promising early results of our research that has been conducted by Dr. Coombs and his team at UM.

“This is a global pandemic, which requires research partnerships and the combined strength of multidisciplinary teams,” Arkady added. “By joining forces with UM, Theralase believes it can develop an elegant solution that will help mitigate this threat quickly and efficiently. Data in four preclinical models in both infectious disease and oncology strongly suggests that the Theralase technology platform has flexibility and bandwidth to be clinically relevant in destruction of numerous cancers and pathogens, including enveloped viruses. Now, with a new pandemic raging, Theralase is working on the development of effective mitigation strategies for the novel coronavirus that encompasses prevention of the disease and effective treatment of patients who contract COVID-19.”

It would seem that we have another focused traetment in developement for our ACT treatment with some tweaks I assume. What could the call the Virus killer treatment ? AVT ! Any how I hope they expedite as quickly as possible. Now I know quickly and Theralase are and odd pair indeed however with the covid pandemic on this may finally get a burner under our mgts butts.
U Manitoba inks deal with Theralase to develop coronavirus vaccine and therapy using photodynamic compounds - University-Industry Engagement Week - Tech Transfer Central